An AI-written leaflet can only be considered for patient use after appropriate clinical, editorial and governance review. Generating readable text is not the same as approving information for distribution. Start by checking whether an existing approved resource already meets the need, then establish who will verify and maintain any new material.
Decide what the leaflet must help someone do
A leaflet about a condition, preparation for an appointment and advice after a consultation have different purposes. Define the intended reader and the action they should be able to take after reading it.
For an original fictional example, a practice wants to explain how patients will receive routine investigation results. The intended task is operational: understand the agreed communication route, what happens if no message arrives and how to seek help when symptoms change. It is not an opportunity for AI to invent generic clinical reassurance.
The first source should therefore include the practice's actual process. A beautifully written paragraph describing a system that does not exist locally is worse than an unpolished but accurate explanation.
Reuse responsibly before rewriting
Check approved local material and relevant established patient resources first. Adaptation may still require permission and review; access to a webpage does not automatically permit reproducing its text, images or layout.
MedlinePlus's content-use guidance, checked on 19 September 2026, illustrates why permissions must be checked at the content level. Some material is public domain, while other material is separately copyrighted and licensed for that site. A single blanket statement about the whole website would be inaccurate.
Linking to an appropriate resource may be preferable to copying it. Where adaptation is permitted, keep attribution and any conditions attached to reuse. Rewriting protected material through an AI tool is not a reliable way to avoid the original permissions question.
Edit meaning before readability
Consider this deliberately flawed, original draft sentence: "If you do not hear from us, your result is normal and no further action is required."
The sentence is short and easy to read. That does not make it suitable. It assumes a communication process, a clinical interpretation and an action that may not match the service's arrangements.
A safer drafting approach is to leave operational details unresolved until confirmed: "Your clinical team will explain how and when you should receive the result. Follow the agreed contact process if that communication does not arrive." Even that wording needs local review before use; it is an example of limiting unsupported assumptions, not a finished leaflet.
The editor should identify each factual claim, the source supporting it and the person authorised to confirm local instructions. Only then should the text be simplified. Readability cannot rescue an inaccurate message.
Test the reader's task
Ask someone from the intended audience to explain what they would do in the situation described. Do not ask only whether the leaflet "looks clear". A favourable impression can coexist with a misunderstanding of the action.
For the fictional results leaflet, useful questions include: how will you expect to hear, what will you do if that does not happen, and does the leaflet tell you what to do about a new concern? The answers reveal whether the document supports the intended task.
This is a proposed usability exercise, not a validated readability assessment or a claim that patient testing has occurred. Record who reviewed the material, what they were asked and what changed as a result.
Avoid designing only for the confident reader who helped write it. Consider language, visual access, digital access and the circumstances in which the information will be used.
Translation is another review step
A translation can be linguistically fluent while changing a clinical qualification or an operational instruction. Conversely, literal translation may preserve words while becoming difficult to understand.
Use the appropriate approved translation and review process for the service. Confirm that contact details, emergency instructions and local pathways remain relevant. Do not assume that a translated leaflet is clinically adapted to a different country merely because it uses the local language.
Keep versions connected. If the English source changes, establish how the translated versions will be reviewed. Otherwise, a corrected master document can coexist with outdated material still being distributed.
Assign ownership before publication
A usable approval record identifies the document, intended audience, clinical reviewer, operational owner, evidence sources, version and review date. It should also state what would trigger an earlier review, such as a changed pathway or a material correction.
Decide where the approved master will live and how older copies will be withdrawn or marked. A PDF saved in several unrelated folders can become difficult to update consistently.
For AI-assisted drafting, record the tool's role as appropriate to the organisation's policy. The important distinction is between assistance with creating text and accountability for the information finally issued. No statement about the tool removes the need for an identifiable human owner.
Keep patient information out of an unnecessary drafting task
A generic leaflet rarely needs a real patient's record as input. Use an abstracted description of the intended task or a fully fictional example when possible. Where personal information is genuinely required, use the approved environment and applicable permissions.
The ICO's anonymisation guidance, checked on 19 September 2026, makes clear that removing obvious identifiers does not by itself establish anonymity. A distinctive story can remain identifiable in context.
Do not confuse a personal after-visit summary with a general leaflet. The former may contain patient-specific information and instructions, requiring a different review and handling process.
Where iatroX belongs
This article is published by iatroX and includes its own role alongside established resources. An approved patient leaflet is usually preferable when it already answers the question. iatroX can support the clinician's background understanding, but a generated explanation should not be presented as automatically approved patient information.
The public iatroX methodology checked on 19 September 2026 describes source-linked reference and output-checking processes. Those are product-design features, not certification of a new leaflet. The final decision to distribute material still rests on the applicable clinical and editorial process.
Frequently asked questions
Is a plain-language AI leaflet ready to give to patients?
Not on readability alone: clinical statements, local instructions, permissions and review ownership still need checking. A clear sentence can be clearly wrong.
Can I copy any MedlinePlus content because it is a public health website?
No: its reuse terms distinguish public-domain material from separately licensed content. Check the exact material and its permissions.
Does an AI disclosure replace clinical approval?
No: it describes how material was produced, not whether it is appropriate for the intended patient and service. Approval and maintenance remain separate responsibilities.
Prepare the underlying clinical explanation with Ask-iatroX →